- Home
- CYN vs SCYX Comparison
CYN vs SCYX Comparison
Compare CYN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- SCYX
- Stock Information
- Founded
- CYN 2013
- SCYX 1999
- Country
- CYN United States
- SCYX United States
- Employees
- CYN N/A
- SCYX N/A
- Industry
- CYN EDP Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- SCYX Health Care
- Exchange
- CYN Nasdaq
- SCYX Nasdaq
- Market Cap
- CYN 28.0M
- SCYX 28.5M
- IPO Year
- CYN 2021
- SCYX 2014
- Fundamental
- Price
- CYN $7.08
- SCYX $0.69
- Analyst Decision
- CYN
- SCYX
- Analyst Count
- CYN 0
- SCYX 0
- Target Price
- CYN N/A
- SCYX N/A
- AVG Volume (30 Days)
- CYN 1.2M
- SCYX 201.9K
- Earning Date
- CYN 08-06-2025
- SCYX 08-11-2025
- Dividend Yield
- CYN N/A
- SCYX N/A
- EPS Growth
- CYN N/A
- SCYX N/A
- EPS
- CYN N/A
- SCYX N/A
- Revenue
- CYN $409,777.00
- SCYX $2,630,000.00
- Revenue This Year
- CYN $1,162.03
- SCYX $410.22
- Revenue Next Year
- CYN $427.83
- SCYX $248.83
- P/E Ratio
- CYN N/A
- SCYX N/A
- Revenue Growth
- CYN N/A
- SCYX N/A
- 52 Week Low
- CYN $3.62
- SCYX $0.66
- 52 Week High
- CYN $1,312.50
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- CYN 39.27
- SCYX 40.13
- Support Level
- CYN $8.20
- SCYX $0.67
- Resistance Level
- CYN $10.04
- SCYX $0.74
- Average True Range (ATR)
- CYN 0.67
- SCYX 0.04
- MACD
- CYN -0.43
- SCYX 0.00
- Stochastic Oscillator
- CYN 0.79
- SCYX 9.74
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.